Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB2103 : 8505C  update : 2022/09/22
CommentHuman cell line derived from thyroid cancer. Poorly differentiated papillary adenocarcinoma. TKG0439 (Deposited from Tohoku Univ.).
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Remarks
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor Obinata, Masuo
Originator Nakamura, N.
Year of deposit 2005
Original cell TKG0439
Animal human < Mammals
Genus Homo
Species sapiens
Tissue thyroid gland
Disease name Poorly differentiated papillary adenocarcinoma
Classification cancer
History Cell Resource Center for Biomedical Research, Tohoku University(TKG0439)
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_1054
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives MEM + 10% FBS
Antibiotics Free
Passage method 0.25% Trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Isozyme LD, NP
STR(human) OK
Images
deposit info
lot info
Reference information Reference 1
User's Publication 6


To topTop
Reference
5037  Ito T, Seyama T, Hayashi Y, Hayashi T, Dohi K, Mizuno T, Iwamoto K, Tsuyama N, Nakamura N, Akiyama M.  Establishment of 2 human thyroid-carcinoma cell-lines (8305c, 8505c) bearing p53 gene-mutations.  Int J Oncol  1994  4(3):583-6  PubMed ID: 21566963

To topTop
User's Publication
16175  Bonaldi E, Gargiuli C, De Cecco L, Micali A, Rizzetti MG, Greco A, Borrello MG, Minna E.  BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells  Int J Mol Sci  2021  22(11):5744  PubMed ID: 34072194
20058  Aoyama M, Takizawa H, Otani T, Inoue S, Kawakita N, Tsuboi M, Bando Y, Uehara H, Kondo K, Tangoku A.  Non‑invasive monitoring of paclitaxel and lenvatinib efficacy against anaplastic thyroid cancer in orthotopic SCID mouse models using small‑animal FDG‑PET/CT.  Oncol Rep  2020  44(4):1709-1716  PubMed ID: 32945510
11296  Itai N, Shimazu T, Kimura T, Ibe I, Yamashita R, Kaburagi Y, Dohi T, Tonozuka T, Takao T, Nishikawa A.  The phosphorylation of sorting nexin 5 at serine 226 regulates retrograde transport and macropinocytosis.  PLoS ONE  2018    PubMed ID: 30419003
4466  Shimamura M, Yamamoto K, Kurashige T, Nagayama Y.  Intracellular redox status controls spherogenicity, an in vitro cancer stem cell marker, in thyroid cancer cell lines.  Exp. Cell Res.  2018  370(2):699-707  PubMed ID: 30053445
12914  Nambu J, Kobayashi T, Hashimoto M, Tashiro H, Sugino K, Shimamoto F, Kikuchi A, Ohdan H.  10.3892/or.2016.4759  Oncol Rep  2016  35(6):3445-52  PubMed ID: 27109060
7971  Sato A, Kudo C, Yamakoshi H, Uehara Y, Ohori H, Ishioka C, Iwabuchi Y, Shibata H.  Curcumin analog GO-Y030 is a novel inhibitor of IKKβ that suppresses NF-κB signaling and induces apoptosis.  Cancer Sci.  2011  102:1045-51  PubMed ID: 21272158



Back Back Return Top Page